Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in Postural Tachycardia Syndrome
NCT03261570Phase 1Completed
- Sponsor
- New York Medical College
- Start
- Jul 2017
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1 trial of pyridostigmine and digoxin in postural orthostatic tachycardia syndrome (POTS) (2 arms), sponsored by New York Medical College. Primary endpoints: Cardiovagal Baroreflex during orthostatic stress at 1 year and Cognitive ability during orthostatic stress at 1 year. Started Jul 2017; status: completed.
02
Drugs
pyridostigminedigoxin
03
Conditions
postural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT03261570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03261570.